Obicetrapib or obicetrapib-ezetimibe for primary hypercholesterolaemia or mixed dyslipidaemia

Obicetrapib or obicetrapib-ezetimibe is in clinical development for treating primary hypercholesterolaemia (PH) or mixed dyslipidaemia in adults on maximally tolerated lipid-lowering therapy, that is patients that fail to reach treatment goals inspite of being on highest tolerated dose of lipid-lowering therapy. High levels of cholesterol in the blood (hypercholesterolaemia) may be caused by genetic defects (as seen in familial (inherited) hypercholesterolaemia) or when genes and other factors such as lifestyle habits interact, as seen in non-familial hypercholesterolaemia. With hypercholesterolaemia, the liver is less able to remove excess ‘bad’ cholesterol, known as low-density lipoprotein cholesterol (LDL-C). This means the LDL-C level in the blood can get too high, increasing the risk of cardiovascular (heart and blood vessel) disease.